nmCRPC VL

SPARTAN: A Study of Apalutamide in Men with M0 Castration-Resistant Prostate Cancer (M0 CRPC) - Alan Bryce

Details
(Length of Presentation and Discussion: 9 minutes) Alan Bryce provides an overview of results from SPARTAN: A Study of Apalutamide (ARN-509) in Men with Non-Metastatic Castration-resistant Prostate Cancer - and the subsequent FDA approval of apalutamide for treatment of men with M0 castration resistant prostate cancer ( M0 CRPC). The presentation includes a review of the data on the primary and se...

Meeting an Unmet Need in the Nonmetastatic Castration Resistant Prostate Cancer Patient Population - Maha Hussain

Details
(Length of Discussion: 22 min) Alicia Morgans and Maha Hussain discuss the Evaluating the Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER) phase III randomized double-blind controlled trial , in the nonmetastatic castration-resistant prostate cancer (nmCRPC) patient population which was first presented at the 2018 ASCO GU meeti...

Changing the Landscape of nmCRPC - The SPARTAN Trial - Eric Small

Details
(Length of Discussion: 25 min) Professor Eric Small, MD talks with Dr. Neal Shore in a post ASCO GU interview on Dr. Eric Small’s plenary presentation on the phase three global SPARTAN trial. A landscape changing treatment for patients with non-metastatic castration resistant prostate cancer. The first drug approved by FDA to satisfy an unmet need for nmCRPC or m0 patients. Dr. Eric Small gives an...

M0 CRPC: Clinical Entity or Diagnostic Dilemma - Brett Carver

Details
Access to all Advanced Prostate Cancer Consensus Conference Video Coverage Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer